Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients

NCT01119937 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237
DRUG: Tiotropium

Sponsor

Novartis Pharmaceuticals